Information Provided By:
Fly News Breaks for April 10, 2018
NVS, AVXS, BIIB
Apr 10, 2018 | 08:15 EDT
Bernstein analyst Aaron Gal believes that Biogen (BIIB) odds of counter-bidding Novartis (NVS) takeout offer for AveXis (AVXS) are low, primarily because of FTC concerns. Nonetheless, the analyst notes that this increases pressure on Biogen's Spinraza as it puts the competing SMA program in the hands of a well-funded, payer-competent, global-reaching company. Gal reiterates an Outperform rating and $318 price target on Biogen's shares.
News For BIIB;AVXS;NVS From the Last 2 Days
There are no results for your query BIIB;AVXS;NVS